Online inquiry

IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2047MR)

This product GTTS-WQ2047MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2047MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3688MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ12696MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ2707MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ1265MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ3205MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ15666MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ11280MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ7596MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW